UK Life Sciences Financial & Corporate News
Financial and corporate news covers changes in the performance, status and internal organisation of UK life sciences businesses. It helps readers follow developments that affect how companies operate, beyond individual products, research programmes and financing rounds.
Sareum Reports Narrower Annual Loss and SDC-1801 Progress
Sareum reported a pre-tax loss of £3.5 million for the year ended 30 June 2026, compared with £4.9 million a year earlier, with no revenue. In its accompanying development update, the company confirmed completion of dosing in the Phase 2-enabling toxicology programme for SDC-1801 in July. Full toxicology results are expected during the fourth quarter of 2026, with further formulation and regulatory work ongoing.
Rezera Files US IPO Registration to Support Phase 3 Ruvonoflast
Rezera, formerly NodThera, filed a Form S-1 registration statement with the US Securities and Exchange Commission on 21 October 2026 for a potential initial public offering. The company is developing NLRP3 inhibitors, including ruvonoflast, which it plans to advance into Phase 3 for peripheral artery disease. The filing does not establish that the share offering has priced, completed or begun trading.
CelLBxHealth Cuts Nine-Month Cash Operating Loss 60% and Targets £3-4M Revenue in 2027
CelLBxHealth has cut its nine-month cash operating loss by 60% to £4.0 million and expects FY26 revenue of about £1.8 million, up 29%, with a target of £3 to 4 million for 2027. The company says existing resources and an expected R&D tax credit extend its cash runway into Q1 2027.
IXICO Expects 28% Revenue Growth to £8.3M for FY26, Ahead of Guidance
IXICO expects FY26 revenue of £8.3 million, up 28% and ahead of its upgraded £8.0 million guidance, driven by a rise in analysis orders in the final quarter. The company ended the year with £10.4 million in cash and a £16.0 million order book, and expects its EBITDA loss to come in better than the £1.7 million guided.
3D Bio-Tissues Becomes BSF Enterprise's Core IP and Manufacturing Hub as milieu.bio Launches
BSF Enterprise has reorganised so that 3D Bio-Tissues holds the group's IP, R&D and manufacturing, while new subsidiary milieu.bio sells its CityMix and CytoBoost media additives to biopharma, cell therapy and cellular agriculture customers. 3D Bio-Tissues will supply milieu.bio at cost-plus and receive royalties on external sales.